Papillary serous carcinoma of the peritoneum

Article Abstract:

Confusion exists among clinicians and pathologists regarding a particular type of tumor that affects the peritoneum (the membrane lining the abdominal cavity) and nearby structures. To better describe this disease entity, results from a study of 74 female patients (average age, 57) are presented. Eight hundred and seventeen women had initially received the diagnosis of serous ovarian cancer; histopathological material was reviewed for patients whose ovaries had appeared normal or minimally diseased, and whose ovaries were no larger than four centimeters in diameter. A discussion is provided of the ways papillary serous carcinoma of the peritoneum (the preferred diagnostic label) is different from other tumor types with which it could be confused. Patients' symptoms included abdominal pain, distention, and gastrointestinal changes. The patients' responses to chemotherapy were rated as complete (disappearance of disease for one month or more); partial (50 percent reduction in the tumor's diameter for at least one month); progressive (50 percent increase in the tumor's diameter); or stable. Almost 64 percent of the patients had complete (22.7 percent) or partial (40.9 percent) responses to chemotherapy. The median survival time for the group was 24 months. This time was not associated with the age of the patient or with the amount of diseased tissue that remained after surgical intervention. Survival was longest for patients who underwent chemotherapy with a combination of drugs than with a single agent; cisplatin was especially effective. Although papillary serous carcinoma of the peritoneum is similar to ovarian cancer in some ways, it should be classified separately. This will facilitate better understanding of the disease and, ultimately, its treatment. (Consumer Summary produced by Reliance Medical Information, Inc.)

Care and treatment, Pelvic cancer

---

Transitional cell carcinoma of the ovary: a matched control study of advanced-stage patients treated with cisplatin-based chemotherapy

Article Abstract:

Cisplatin-based chemotherapy may be more effective for treating ovarian cancer patients with transitional cell carcinoma than for those with serous carcinoma. Among 124 women in the advanced stages of ovarian cancer who underwent cisplatin-based chemotherapy, 62 had transitional cell carcinoma and 62 had serous carcinoma. Thirty-seven percent of the patients with transitional cell carcinoma experienced a complete surgical response, compared with only 11% of the those with serous carcinoma. Patients with transitional cell carcinoma survived an average of 52 months, compared with an average of 22 months for the patients with serous carcinoma.

Health aspects, Evaluation, Drug therapy, Ovarian cancer, Chemotherapy, Cisplatin

---

Similar abstracts:

• Abstracts: Treatment of sickle cell anemia with hydroxyurea and erythropoietin. Reversing ontogeny
• Abstracts: Treatment of acute vascular occlusions with intra-arterial urokinase. Pathogenesis, diagnosis and treatment of thrombosis
• Abstracts: Low-dose aspirin: II. Relationship of angiotensin II pressor responses, circulating eicosanoids, and pregnancy outcome
• Abstracts: Death in shigellosis: incidence and risk factors in hospitalized patients. Therapy for Shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin
• Abstracts: Reflections of the self: atypical misidentification and delusional syndromes in two patients with Alzheimer's disease

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.